Zdrowie i gospodarka · 27/12/1999
Withdrawal of Guidance Document on Selegiline Hydrochloride Tablets
The Food and Drug Administration (FDA) is withdrawing a guidance for industry entitled ``Selegiline Hydrochloride Tablets: In Vivo Bioequivalence and In Vitro Dissolution Testing.'' This guidance, which was issued in December 1995, is being withdrawn because it does not represent current agency thinking on in vivo bioequivalence (BE) and in vitro testing for selegiline hydrochloride.